United States: Post Exclusivity Issues For Biologics

Investments in research resulting in new drug inventions have long taken advantage of patent protection, but such investments may also benefit from market exclusivities granted by the Food and Drug Administration (the "FDA"). Both patent and market exclusivities encourage and protect the significant innovation and investments required to bring a new drug to market.1

For typical small molecule pharmaceuticals, the Hatch-Waxman Act established a "regulatory framework that sought to balance incentives for continued innovation by research-based pharmaceutical companies and opportunities for market entry by generic drug manufacturers."2 Since generic versions of small molecule drugs may be chemically identical to the brand name version of the drug, a generic manufacturer can rely on FDA testing already performed on the brand name drug to support an application for approval of the generic version. This greatly increases the likelihood of entry of generic small molecule drugs into existing drug markets. Without the protections of patent rights and exclusivity incentives, pharmaceutical companies would have diminished incentives for the substantial investment to bring new small molecule drugs to market, since drug prices drop precipitously when protection expires. In the case of traditional small molecule drugs, typically manufactured through chemical synthesis, dramatic price drops of 50-60% are not unexpected.3 Hence the need for balance in marking the ambit of protection and exclusivity: too small and investment in drug innovation is discouraged; too broad, competition and consequent price reductions are too long delayed.

The challenge of striking such balances as to biologic drugs is far greater, or at least more challenging, than with respect to small molecule drugs. For unlike small molecule drugs, biologic drugs are protein-based molecules derived from living matter or manufactured through forms of biotechnology, which are of greater size and complexity than typical pharmaceuticals. Therefore, even after the patent rights and/or exclusivity rights expire for a biologic, significant technological barriers to market entry may remain after such rights expire. As a result, dramatic price decreases may not necessarily follow quickly in the wake of the expiration of patent or market exclusivities for a brand name biologic and the entry of a biologic competitor. But one must be wary of generalities: prices may in fact dramatically drop as to biologic drugs.

The Biologics Price Competition and Innovation Act of 2009 ("BPCI Act"), which became law on March 23, 2010, attempts to strike a similar balance as to biologics as Hatch-Waxman had for small molecule drugs, taking into account the technical challenges of biologics. The BPCI Act's abbreviated drug approval process is loosely modeled on that used for generic small molecule drugs, creating an abbreviated drug approval process for biologic drugs ("follow-on biologics") that are shown to be "biosimilar" or interchangeable with the brand name ("licensed") biologic drugs listed by the FDA.4 The FDA's Center for Drug Evaluation and Research provides a list of brand name biologic drugs ("reference products").

But the BPCI only sets a statutory framework. The issue is setting the balance between encouraging innovation and expanding competition. As we mentioned, the complex nature of biologic drugs raises the question of whether follow-on biologics are as safe or effective in treatment of patients as their reference products. Consequently, a follow-on biologic may require additional animal and clinical testing before gaining FDA approval, perhaps making it harder for a follow-on biologic to enter the market, even if its reference product is no longer protected by patent coverage or market exclusivity.

Occasionally though, competitors will not face the same technical challenges in entering the market with a follow-on biologic. Where a reference product is composed from molecules already well-known and established in the market, it may be much easier for competitors to produce follow-on biologics. For example, this may be true in the case of antibody-drug conjugates (ADC)or immunoconjugates, which combine small molecules and known antibodies. A pharmaceutical manufacturer of an ADC may not face the same technical hurdles as a manufacturer tackling an unknown large complex molecule. Instead, the challenges to market entry for an ADC may not be all that different from synthesizing a small molecule drug. In such instances, if generic versions of the antibody have already been manufactured and the small molecule is well-known, a follow-on biologic ADC could be produced with substantial confidence that the follow-on biologic ADC will have comparable safety, efficacy and ease of use to that of the reference product, sufficient to warrant FDA approval. In such an instance, the price of a post-patent rights, post-market exclusivity biologic may be expected to behave more like a small molecule drug facing generic competition than other biologics.

The BPCI Act itself provides that its 12 year market exclusivity for reference product biologics does not apply to minor changes to a biologic, such as a "new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength" or "a modification to the structure of the biological product that does not result in a change in safety, purity or potency." 42 U.S.C. § 262(k)(7)(c). Indeed, extending exclusivity for brand name biologics comprised of previously well-known components, which may have already enjoyed their own market exclusivities, may raise anti-trust concerns not unlike those raised by the FTC in its Brief as Amicus Curiae, Mylan Pharm., Inc. v. Warner Chilcott Pub. Co., No. 12-3824 (E.D. Pa. Dec. 3, 2012), ECF No. 122. In that amicus brief, the FTC asserted that "pharmaceutical product redesigns can constitute exclusionary conduct" where the brand company withdraws the original product from the market or "achieve[s] the same result through indirect means . . . ." Id. at 10, 13. The brief went on to assert that the plaintiffs had asserted a plausible claim that "the defendants' product reformulations constitute an unlawful means of preserving monopoly power in violation of Section 2 of the Sherman Act." Id. at 14. Attempting to maintain market exclusivity through impermissible conduct that has the effect of effectively lengthening the term of patent rights or improperly broadening the scope of a patent could implicate the policy concerns underlying patent misuse doctrine. See Hovenkamp, Janis, Lemley and Leslie, IP and Antitrust, Chp 3 (2nd ed. Update 2014) (general description of patent misuse doctrine). See also, Princo Corp. v. International Trade Commission, 96 USPQ2d 1233, 1239 (Fed. Cir. 2010) ("The doctrine of patent misuse is thus grounded in the policy-based desire to 'prevent a patentee from using the patent to obtain market benefit beyond that which inheres in the statutory patent right."'). Cf. Brulotte v. Thys Co., 379 U.S. 29, 32 (1964) ("a patentee's use of a royalty agreement that projects beyond the expiration date of the patent is unlawful per se"; the continuing vitality of Brulotte will be the subject of Supreme Court review this term. See, Kimble v. Marvel Enterprises, Inc., 727 F.3d 856, (9th. Cir. 2013), petition for cert. granted, 82 USLW 3379, No. 13-720, (Dec. 12, 2014) (the Supreme Court will consider whether a royalty agreement that projects beyond the expiration date of the patent is unlawful per se)). In addition, minor changes and reformulations to well-known products can, of course, also be attacked under the patent laws on grounds of lack of novelty or anticipation and obviousness.

Ultimately, whether any given brand name biologic drug is vulnerable to market entry by a follow-on biologic may depend on the degree of its reliance on well-understood components. As described for ADC's above, some brand name biologics may therefore be vulnerable to the typical 50-60% price drop seen in cases of generic small molecule competition. Accordingly, a careful review of the composition of a biologic drug is another factor that merits consideration in evaluating the advantages that may be provided by exclusivities.

Footnotes

1. While calculating the costs to bring a drug to market will vary widely based upon a multitude of factors, at least one recent study released by the Tufts Center for the Study of Drug Development, has projected the current out of pocket costs from development through market approval of the drug at approximately $1.4 billion. "Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion", November 18, 2014, Tufts Center for the Study of Drug Development. http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study.

2. Prepared Statement of the Federal Trade Commission Before the Committee on Judiciary, United States Senate (June 17, 2003).

3. Frank R. Lichtenberg and Gautier Duflos, "Time Release: The Effect of Patent Expiration on U.S. Drug Prices, Marketing, and Utilization by the Public," Medical Progress Report, No. 11, October 2009.

4. A follow-on biologic is biosimilar to a brand-name product if it is deemed to be "highly similar to the reference product notwithstanding minor differences in clinically inactive components" and "there are no clinically meaningful differences between the [biosimilar] and the reference product in terms of safety, purity, and potency of the product." 42 U.S.C. § 262(i)(2). A follow-on biologic is interchangeable if it meets the standard for biosimilarity and (1) it can be expected to produce the same clinical result as the reference product in any given patient and (2) for a product administered more than once, the risk, in terms of safety or diminished efficacy of switching between the two products, is not greater than the use of the reference product without such alternation. 42 U.S.C. § 262(k)(4).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions